Dentsply Sirona to Report Q1 2026 Earnings Amid Sell Rating and $840M Revenue Forecast

TL;DR: Dentsply Sirona reports Q1 2026 earnings on May 5 after market close, with consensus revenue of $840.1 million and earnings per share of $0.28; the stock carries a Zacks Sell rating.

Context Dentsply Sirona (ticker XRAY) is a leading dental equipment and consumables provider. The company is in the early stages of a multi‑year “Return‑to‑Growth” plan that emphasizes innovation, commercial reorganization, and clinical education. Recent quarters have shown earnings volatility, with the prior quarter missing consensus by 3.57% and an average surprise of 7.73% over the last four quarters.

Key Facts - The earnings release is scheduled for May 5, after the market closes. - Zacks consensus estimates project Q1 revenue at $840.1 million and earnings per share (EPS) at $0.28. - Dentsply Sirona holds a Zacks Rank of #4, which translates to a Sell recommendation. - Management expects continued softness in the U.S. market, tariff pressures, and dealer inventory adjustments of roughly $30 million in the first half of 2026. - Segmentally, Connected Technology Solutions, implants, and orthodontics remain weak, while Essential Dental Solutions and Wellspect Healthcare show relative stability. - International markets, especially Europe, are expected to offset some domestic weakness.

What It Means The consensus revenue forecast of $840.1 million suggests modest top‑line growth, but the Sell rating signals that analysts anticipate near‑term challenges outweigh potential upside. The “Return‑to‑Growth” initiatives require elevated spending on R&D and commercial restructuring, likely compressing margins in the short term. Dealer inventory reductions and a shift toward a drop‑ship model could further pressure volumes, especially in equipment and CAD/CAM categories where inventory remains below historic averages.

Investors will watch for signs that the strategic transformation is gaining traction—particularly any improvement in implant sales, dealer partnership metrics, and U.S. market stabilization. A better‑than‑expected EPS could hint that cost controls are taking effect earlier than projected, while a miss would reinforce the Sell stance and could pressure the stock further.

Looking ahead, market participants should monitor the May 5 earnings release for actual revenue and EPS numbers, inventory trends, and management commentary on the progress of the Return‑to‑Growth plan, as these will shape the stock’s trajectory for the rest of 2026.